Plunkett's Biotech and Genetics Industry Almanac 2009
By

Rating

Product Description
Product Details

Table of Contents

PLUNKETT'S BIOTECH & GENETICSINDUSTRY ALMANAC 2009CONTENTSA Short Biotech & Genetics Industry Glossary xiiIntroduction 1How to Use This Book 3Chapter 1: Major Trends Affecting the Biotech & Genetics Industry 71) The State of the Biotechnology Industry Today 72) A Short History of Biotechnology 113) Ethanol Production Soared, But a Market Glut May Slow Expansion 124) New Money Pours into Biotech Firms/Mergers and Acquisitions Surge Ahead 145) Major Drug Companies Bet on Partnerships With Smaller Biotech Research Firms 156) From India to Singapore to Australia, Nations Compete Fiercely in Biotech Development 157) Gene Therapies and Patients' Genetic Profiles Promise a Personalized Approach to Medicine 178) New Kinase Inhibitors Are Breakthrough Drugs for Cancer Treatment-Many More Will Follow 199) Few New Blockbusters: Major Drug Patents Expire While Generic Sales Soar 1910) Biotech and Orphan Drugs Pick Up the Slack as Blockbuster Mainstream Drugs Age 2111) Biogenerics (Follow-on Biologics) are in Limbo in the U.S. 2212) Breakthrough Drug Delivery Systems Evolve 2313) Stem Cells-Controversy in the U.S. Threatens to Leave America Far Behind in the Research Race 2414) Stem Cell Funding Trickles in the U.S. at the Federal Level While a Few States Create Funding ofTheir Own 2515) Stem Cells-Therapeutic Cloning Techniques Advance 2616) Stem Cells-A New Era of Regenerative Medicine Looms 2717) Nanotechnology Converges with Biotech 2918) Agricultural Biotechnology Scores Breakthroughs but Causes Controversy/Selective BreedingOffers a Compromise 3019) Focus on Vaccines 3220) Ethical Issues Abound 3321) Technology Discussion-Genomics 3322) Technology Discussion-Proteomics 3423) Technology Discussion-Microarrays 3424) Technology Discussion-DNA Chips 3425) Technology Discussion-SNPs (A"SnipsA") 3526) Technology Discussion-Combinatorial Chemistry 3527) Technology Discussion-Synthetic Biology 3528) Technology Discussion-Recombinant DNA 3629) Technology Discussion-Polymerase Chain Reaction (PCR) 36Chapter 2: Biotech & Genetics Industry Statistics 37Biotech Industry Overview 38Global Biotechnology at a Glance: 2007 39Growth in Global Biotechnology: 2006-2007 4020 Largest Global Pharmaceutical Companies: 2006-2007 41Global Area of Biotech Crops by Country: 2007 42Biotechnology Financing, U.S., Europe & Canada: 2006-2007 43U.S. Biotechnology at a Glance: 2006-2007 44Quarterly Breakdown of Biotechnology Financings, U.S. & Canada: 2007 45Ernst & Young Survival Index, U.S. & Canadian Biotechnology Companies: 2006-2007 46Domestic & Foreign Pharmaceutical Sales, PhRMA Member Companies: 1970-2007 47Sales by Geographic Area, PhRMA Member Companies: 2006 48Domestic Biopharmaceutical R&D & R&D Abroad, PhRMA Member Companies: 1970-2007 49Domestic Biopharmaceutical R&D Breakdown, PhRMA Member Companies: 2006 50R&D By Global Geographic Area, PhRMA Member Companies: 2006 51Biologics & Biotechnology R&D, PhRMA Member Companies: 2006 52R&D as a Percentage of U.S. Biopharmaceutical Sales, PhRMA Member Companies: 1970-2007 53U.S. Exports & Imports of Pharmaceutical Products: 2002-1st Quarter 2008 54Summary of Value of U.S. Shipments of Pharmaceutical Preparations, Except Biologicals: 2003-2007 55Value of U.S. Shipments of Pharmaceutical Preparations, Except Biologicals, Detailed: 2007 56Federal R&D & R&D Plant Funding for General Science & Basic Research, U.S.: Fiscal Years2006-2008 61Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Years 2007-2009 62National Health Expenditure Amounts by Type of Expenditure, U.S.: Selected Calendar Years,2002-2017 63Prescription Drug Expenditures, U.S.: 1965-2016 64U.S. Prescription Drug Expenditures, Aggregate & Per Capita Amounts, Percent Distribution:Selected Calendar Years, 2002-2017 66The U.S. Drug Discovery & Approval Process 67U.S. FDA Approval Times for New Drugs: 1993-2007 68U.S. FDA Approval Times for New Molecular Entities (NMEs): 1993-2007 69U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals:1993-2007 70Total U.S. Biotechnology Patents Granted per Year by Patent Class: 1977-2006 71Plant-Derived Pharmaceuticals for the Treatment of Human Diseases that are in the Pipeline forCommercialization: 2007 72Employment in Life & Physical Science Occupations by Business Type, U.S.: May 2007 73Domestic Biopharmaceutical R&D Scientific, Professional & Technical Personnel by Function,PhRMA Member Companies: 2006 74Chapter 3: Important Biotech & Genetics Industry Contacts 75(Addresses, Phone Numbers and Internet Sites)Chapter 4: THE BIOTECH 400:Who They Are and How They Were Chosen 108Industry List, With Codes 109Index of Rankings Within Industry Groups 111Alphabetical Index 121Index of Headquarters Location by U.S. State 125Index of Non-U.S. Headquarters Location by Country 129Index by Regions of the U.S. Where the Firms Have Locations 131Index by Firms with Operations Outside the U.S. 137Individual Profiles on Each of THE BIOTECH 400 140Additional IndexesIndex of Hot Spots for Advancement for Women/Minorities 548Index by Subsidiaries, Brand Names and Selected Affiliations 550

About the Author

Jack W. Plunkett is CEO & Publisher of Plunkett Research, Ltd., a Houston-based provider of market research and industry information in printed and electronic formats. Plunkett's client list includes 5,000 leading corporations, universities and government agencies worldwide. Plunkett's research products are distributed electronically through subscriptions to its website, www.plunkettresearch.com, and around the globe by major booksellers and news distributors. Jack Plunkett's work has been widely covered by hundreds of magazines, newspapers and broadcast stations, including stories in USA Today and Inc. Magazine. Plunkett is frequently interviewed as an expert source by publications such as Newsweek, The Wall Street Journal. The New York Times and Investor's Business Daily, media outlets such as NPR's Marketplace, ABC, and CBS Marketwatch, as well as local and regional newspapers and national columnists.

Reviews

A"A...A book/CD-ROM reference guide to the business side of biotech, genetics, proteomics and related services. Offers profiles of 400 leading biotech companies, plus overviews of trends in biotech, technology, finances and careers which will help readers understand the uses and implications of such technologies as tissue engineering, recombinant DNA and genetically engineered agricultural productsA... The CD-ROM contains corporate profiles (of 400 leading biotech companies) and executive names by title, and can be used for mail merge and financial charts.A"SciTech Book NewsA"For business researchers and job seekers, this almanac provides an overview of leading biotechnology firms and descriptions of emerging technologyA... The company and industry overviews make this a worthwhile addition to business and career reference collections.A"CHOICE magazineA"Extensive indexing adds to the volume's usefulness.A"Booklist magazineA"This volumeA...has pulled together a large collection of companies in this industry and provides a ready reference for a variety of information in one place.A"RUSQ Quarterly MagazineA"The simple and straight-forward structure and presentation of information is a real asset, making for very intuitive application. A companion CD enables the creation of mailing lists, permits the creation of customized spreadsheets and databases and the ability to sort, filter and view the corporate profiles.A"A"Plunkett's Biotech and Genetics Industry Almanac is an essential addition to any biotechnology executive's bookshelf.A"Yali Friedman, Biotech/Biomedical Editor, About.comA"One more fine example of the fine publications offered by Plunkett Research. This reference book is particularly timely given the considerable interest in biotech and genetics from scientific, investment and entrepreneurial audiencesA...Will be an excellent source for nearly any kind of library.A"American Reference Books Annual

Ask a Question About this Product More...
 
This title is unavailable for purchase as none of our regular suppliers have stock available. If you are the publisher, author or distributor for this item, please visit this link.

Back to top